Al Hammadi Holding — Capital/Financing Update 2021

Nov 9, 2021

Al Hammadi Company for Development and Investment Announces the Purchase of 35% of Sudair Pharmaceuticals in the value of 118,125,000 saudi riyals

4007 · 09/11/2021 15:44:05 · Announcement #65556 · View on Saudi Exchange

Al Hammadi Company for Development and Investment Announces the Purchase of 35% of Sudair Pharmaceuticals in the value of 118,125,000 saudi riyals

Element List	Explanation
Introduction	Al Hammadi Company for Development and Investment announces the satisfaction of all the conditions of the Transaction, obtaining all required approvals and completion of all required regulatory formalities and agreed terms for transferring the Sale Shares in Sudair Pharmaceuticals Company to Al Hammadi Company for Development and Investment on 2021/11/9, including obtaining of the no objection letter in respect of the Transaction issued by the General Authority for Competition and amendment of Sudair Pharmaceuticals Company articles of association to reflect the Transaction.
Transaction Details	purchase the entire Stake shares of the Gulf Investment Corporation (GIC) , which represents 35% of Sudair Pharmaceuticals Company, the owner and developer of Sudair Complex for Specialized Pharmaceutical Industries
Transaction Value	118,125,000 saudi riyals
Transaction Terms	the due diligence examination of the company's financial, legal, administrative and operational conditions and Status have been completed

the approval of the relevant authorities have been secured

the financial valuation has been completed Parties of the Transaction seller Gulf Investment Corporation (GIC)

buyer Al Hammadi Company for Development and Investment Transaction Funding Method internal cash flow Transaction Execution Date 2021-11-09 Corresponding to 1443-04-04 Description of the Business of the Asset forming the Subject Matter of the Transaction manufacturing of cancer treatments (oral and intravenous) Financial Statements for the Last Three Years of the Asset forming the Subject Matter of the Transaction 2018 not applicable as the company start the trial operations in 2019

2019 net profit of 10 million riyals

2020 net profit of 23 million riyals Transaction reasons The acquisition is in line with Al Hammadi Company’s growth plans and the Kingdom’s Vision 2030 to nationalize and localize advanced industries and technologies Expected Impact of the Transaction on the Company and Its Operations increase the sales of the pharma sector in the company Related Parties none

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.